Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.220
-0.070 (-5.43%)
At close: Jun 13, 2025, 4:00 PM
1.211
-0.009 (-0.73%)
After-hours: Jun 13, 2025, 6:34 PM EDT
Werewolf Therapeutics Revenue
Werewolf Therapeutics had revenue of $1.14M in the twelve months ending March 31, 2025, down -92.95% year-over-year. In the year 2024, Werewolf Therapeutics had annual revenue of $1.89M, down -90.55%.
Revenue (ttm)
$1.14M
Revenue Growth
-92.95%
P/S Ratio
47.11
Revenue / Employee
$24,848
Employees
46
Market Cap
54.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HOWL News
- 2 days ago - Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewsWire
- 16 days ago - Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewsWire
- 25 days ago - HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewsWire
- 4 weeks ago - Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit - GlobeNewsWire
- 5 weeks ago - Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting - GlobeNewsWire
- 5 weeks ago - Werewolf Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - GlobeNewsWire